Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells.

The international journal of biochemistry & cell biology - 1 Sept 2020

Liu Jing, Yang Xu, Liang Qing, Yu Yan, Shen Xiaoying, Sun Guangchun

Abstract excerpt

Sorafenib resistance is a classic problem related to the treatment of advanced hepatocellular carcinoma (HCC). There is a recognized need to explore new drug resistance mechanisms and develop novel strategies to overcome the acquired resistance to sorafenib. Although one study has showed that the anti-epileptic drug valproic acid (VPA) could sensitize transforming growth factor-β (TGF-β)-induced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Liver Neoplasms

Share to Receptor, Notch1

Share to Sorafenib

Share to Valproic Acid

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 32750425
DOI: 10.1016/j.biocel.2020.105820

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells.PMID 32750425Read ↗

NOTCH1 regulates the DNA damage response and sorafenib resistance by activating ATM in hepatocellular carcinomaSemantic proximity Read ↗

Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.Semantic proximity Read ↗

Repurposing Antiepileptic Drugs for Cancer: A Promising Therapeutic StrategySemantic proximity Read ↗

Decitabine regulates the resistance of Hep3B to sorafenib through demethylationSemantic proximity Read ↗

Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinomaSemantic proximity Read ↗

Exosomal CircRNA-MANBA Mediates Hepatocellular Carcinoma Sorafenib Resistance via miR-1290/CD109/p-STAT3 AxisSemantic proximity Read ↗

ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.Semantic proximity Read ↗

Could valproic acid be an effective anticancer agent? The evidence so farSemantic proximity Read ↗

Hypercholesterolemia-induced impairment in sorafenib functionality is overcome by avasimibe co-treatmentSemantic proximity Read ↗

MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agentsSemantic proximity Read ↗

Downregulation of SSR2 enhanced the sensitivity of hepatocellular carcinoma cells to cisplatin through Hippo pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.